**Tools for Practice** is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. <u>www.acfp.ca</u>

October 28, 2019 (<u>en français</u>)



Just wait a minute: Point-of-care testing for Group A Streptococcal pharyngitis

Clinical Question: In patients with sore throat, how accurate are point-of-care tests in the diagnosis of Group A beta-hemolytic streptococcal (GABHS) pharyngitis?

Bottom Line: Point-of-care testing, including rapid antigen detection tests and newer nucleic acid detection tests for GABHS pharyngitis are useful for ruling in a diagnosis of GABHS when positive (specificity 95%-99%). Nucleic acid detection tests may be more sensitive than rapid antigen detection tests (92% versus 85%). While immediate testing and treatment may not always be required, populations at increased risk of GABHS complications, such as Canada's Indigenous populations, are more likely to benefit.

**Evidence:** 

- Rapid antigen detection tests versus culture (3 systematic reviews, 43-98 studies including 18,464-101,121 patients):<sup>1-3</sup>
  - Sensitivity consistently ~85%, specificity consistently ~95%.<sup>1-3</sup>
  - Positive likelihood ratio (LR+) 16.8, Negative likelihood ratio (LR-) 0.16.
- Nucleic acid detection tests versus culture:
  - 1 systematic review, 6 studies (1937 patients):<sup>3</sup>
    - Sensitivity=92%, specificity=99%.
    - LR+ 92, LR- 0.08.
  - Evidence published after above reviews:<sup>4-6</sup>
    - Sensitivity=89-100%, specificity=91-100%.
- No significant difference in point-of-care performance between adult and pediatric populations.<sup>1-3</sup>
- Limitations: included studies had high heterogeneity, rapid testing not currently funded publicly.

## Context:

- LR+ above 10 indicates test is a good help at ruling-in diagnosis.
- Clinical decision rules (i.e. CENTOR) have limited predictive value for diagnosing GABHS pharyngitis:<sup>7</sup>
  - Meta-analysis (11 studies):<sup>7</sup> Sensitivity=49% specificity=82%, LR+ 2.68.

- Empiric treatment for sore throat is common (~60%).<sup>8</sup> Point-of-care testing may improve appropriate antibiotic prescribing.<sup>9</sup>
- Antibiotics for GABHS significantly reduces:<sup>10</sup>
  - Sore throat at day three: 44% versus 71%, number needed to treat (NNT)=4.
  - Peritonsillar abscess 0.1% versus 2%, NNT=47.
  - Rheumatic fever 0.6% versus 1.7%, NNT=90.
    - (rheumatic fever data from pre-1950, incidence has declined significantly in developed countries).
- Populations with higher incidence of GABHS complications, such as Canada's Indigenous population, are more likely to benefit from antibiotic treatment.<sup>11-13</sup>
- Many international guidelines consider GABHS pharyngitis self-limiting and do not recommend antibiotic treatment.<sup>14</sup>
- Delayed antibiotic prescriptions decrease antibiotic utilization with no significant impact on symptom duration, or clinical outcomes, in GABHS pharyngitis.<sup>15</sup>

## Authors:

Rodger Craig MPH, Christina Korownyk MD CCFP

## **Disclosures:**

Authors do not have any conflicts of interest to declare.

## **References:**

- 1. Stewart EH, Davis B, Clemans-Taylor BL, et al. PLoS One. 2014 4;9(11):e111727.
- Cohen JF, Bertille N, Cohen, R, et al. Cochrane Database Syst Rev. 2016; 2016(7):CD010502.
- 3. Lean WL, Arnup S, Danchin M, et al. Pediatrics. 2014; 134(4):771-81.
- 4. Berry GJ, Miller CR, Moreno Prats M, et al. J Clin Microbiol. 2018; 56(3):e01310-17.
- 5. Wang F, Tian Y, Chen L, et al. Clin Pediatr (Phila). 2017 Oct; 56(12):1128-1134.
- 6. Weinzierl EP, Jerris RC, Gonzalez MD, et al. Am J Clin Pathol. 2018 Jun 19 [epub ahead of print].
- 7. Aalbers J, O'Brien KK, Chan W, et al. BMC Med. 2011; 9:67.
- 8. Barnett ML, Linder JA. JAMA Intern Med. 2014; 174(1):138-40.
- 9. Rao A, Berg B, Quezada T, *et al*. BMC Pediatr. 2019; 19(1):24.
- 10. Spinks A, Glasziou PP, Del Mar CB. Cochrane Database Syst Rev. 2013 Nov 5;(11):CD000023.
- 11. Bocking N, Matsumoto CL, Loewen K, *et al*. Open Forum Infect Dis. 2016; 4(1):ofw243.
- 12. Madden S, Kelly L. Can Fam Physician. 2009; 55(5):475-8.
- 13. Ralph AP, Holt DC, Islam S, et al. Open Forum Infect Dis. 2019; 6(4):ofz097.
- 14. Van Brusselen D, Vlieghe E, Schelstraete P, *et al*. Eur J Pediatr. 2014 Oct;173(10):1275-83.
- 15. Spurling GK, Del Mar CB, Dooley L, *et al*. Cochrane Database Syst Rev. 2017 Sep; 2017(9):CD004417.

**Tools for Practice** is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic

integrity. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at <a href="http://bit.ly/signupfortfps">http://bit.ly/signupfortfps</a>. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.